What does GEVA PHARMA do?

GEVA PHARMA is a logistics company in Oudenaarde. Private Limited, started on 9 August 1985, 1 establishment.

What is the address of GEVA PHARMA?

The registered office of GEVA PHARMA is located at Diependale 8, 9700 Oudenaarde.

Is GEVA PHARMA still active?

Yes. According to the CBE (30 October 2026) GEVA PHARMA is active, legal situation “Normale toestand”, started on 9 August 1985.

Is GEVA PHARMA registered on Peppol?

Yes, GEVA PHARMA is registered on the Peppol network with ID 0208:0427597576.

What is the enterprise number of GEVA PHARMA?

The enterprise number of GEVA PHARMA is BE0427597576.

When was GEVA PHARMA founded?

GEVA PHARMA was founded on 9 August 1985.

Who are the directors of GEVA PHARMA?

According to the 2025 annual accounts, the directors of GEVA PHARMA are: Philippe Verzele, Conrad Pharma BV.

Is GEVA PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 August 1985; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did GEVA PHARMA make in 2025?

GEVA PHARMA posted a profit after taxes of € 81,596 in financial year 2025.

What is the revenue of GEVA PHARMA?

As a small company, GEVA PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 229,726.

How much does an employee at GEVA PHARMA earn?

The average wage cost per full-time employee at GEVA PHARMA was € 61,000 in 2025: staff costs of € 109,757 for 1.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does GEVA PHARMA have?

According to the 2025 annual accounts, GEVA PHARMA has 1.8 full-time equivalents (FTE).

GEVA PHARMA (Private Limited) - Oudenaarde - BE0427597576

Dossier GEVA PHARMA, printed on 30 October 2026 from databakkes.be/en/0427597576/geva-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

GEVA PHARMA from Oudenaarde, company number BE0427597576, closed financial year 2025 with a result of € 81,596 after tax. For that financial year GEVA PHARMA recorded a gross margin of € 229,726 and equity of € 190,377. Compared with financial year 2024, the result moved from € 86,846 to € 81,596. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Healthy

€ 190,377

▼ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 81,596

▼ 6% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 222,425

▼ 1% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 96,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

1.8

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 109,757

▼ 1% vs 2024

€ 61,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt ≈ 25 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 251,794

▼ 4% vs 2024

€ 10,142 is repaid this year. At this pace the long-term loan is gone in ≈ 25 years.

Owed to suppliers

€ 55,414

▼ 33% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 53,329

▼ 17% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 250,918 Gross margin 2022: € 250,918 First fiscal year in the series	€ 300,921 Gross margin 2023: € 300,921 ▲ 20% vs 2022 (€ 250,918) Favourable step	€ 244,379 Gross margin 2024: € 244,379 ▼ 19% vs 2023 (€ 300,921) Unfavourable step	€ 229,726 Gross margin 2025: € 229,726 ▼ 6% vs 2024 (€ 244,379) Unfavourable step	▼ 6%
Profit after taxes	€ 93,505 Profit after taxes 2022: € 93,505 First fiscal year in the series	€ 129,688 Profit after taxes 2023: € 129,688 ▲ 39% vs 2022 (€ 93,505) Favourable step	€ 86,846 Profit after taxes 2024: € 86,846 ▼ 33% vs 2023 (€ 129,688) Unfavourable step	€ 81,596 Profit after taxes 2025: € 81,596 ▼ 6% vs 2024 (€ 86,846) Unfavourable step	▼ 6%
Equity	€ 184,247 Equity 2022: € 184,247 First fiscal year in the series	€ 207,935 Equity 2023: € 207,935 ▲ 13% vs 2022 (€ 184,247) Favourable step	€ 204,781 Equity 2024: € 204,781 ▼ 2% vs 2023 (€ 207,935) Unfavourable step	€ 190,377 Equity 2025: € 190,377 ▼ 7% vs 2024 (€ 204,781) Unfavourable step	▼ 7%
Total debts	€ 467,239 Total debts 2022: € 467,239 First fiscal year in the series	€ 505,002 Total debts 2023: € 505,002 ▲ 8% vs 2022 (€ 467,239) Unfavourable step	€ 503,095 Total debts 2024: € 503,095 Unchanged (€ 505,002) Favourable step	€ 460,783 Total debts 2025: € 460,783 ▼ 8% vs 2024 (€ 503,095) Favourable step	▼ 8%
Cash	€ 186,223 Cash 2022: € 186,223 First fiscal year in the series	€ 170,344 Cash 2023: € 170,344 ▼ 9% vs 2022 (€ 186,223) Unfavourable step	€ 223,639 Cash 2024: € 223,639 ▲ 31% vs 2023 (€ 170,344) Favourable step	€ 222,425 Cash 2025: € 222,425 ▼ 1% vs 2024 (€ 223,639) Unfavourable step	▼ 1%
Land & buildings	€ 48,575 Land & buildings 2022: € 48,575 First fiscal year in the series	€ 36,824 Land & buildings 2023: € 36,824 ▼ 24% vs 2022 (€ 48,575) Unchanged	€ 81,667 Land & buildings 2024: € 81,667 ▲ 122% vs 2023 (€ 36,824) Unchanged	€ 69,238 Land & buildings 2025: € 69,238 ▼ 15% vs 2024 (€ 81,667) Unchanged	▼ 15%
Retained profit	€ 165,527 Retained profit 2022: € 165,527 First fiscal year in the series	€ 189,215 Retained profit 2023: € 189,215 ▲ 14% vs 2022 (€ 165,527) Favourable step	€ 186,061 Retained profit 2024: € 186,061 ▼ 2% vs 2023 (€ 189,215) Unfavourable step	€ 171,657 Retained profit 2025: € 171,657 ▼ 8% vs 2024 (€ 186,061) Unfavourable step	▼ 8%
Dividend	€ 96,000 Dividend 2022: € 96,000 First fiscal year in the series	€ 106,000 Dividend 2023: € 106,000 ▲ 10% vs 2022 (€ 96,000) Unchanged	€ 90,000 Dividend 2024: € 90,000 ▼ 15% vs 2023 (€ 106,000) Unchanged	€ 96,000 Dividend 2025: € 96,000 ▲ 7% vs 2024 (€ 90,000) Unchanged	▲ 7%
Bank debt	€ 161,124 Bank debt 2022: € 161,124 First fiscal year in the series	€ 151,527 Bank debt 2023: € 151,527 ▼ 6% vs 2022 (€ 161,124) Favourable step	€ 261,751 Bank debt 2024: € 261,751 ▲ 73% vs 2023 (€ 151,527) Unfavourable step	€ 251,794 Bank debt 2025: € 251,794 ▼ 4% vs 2024 (€ 261,751) Favourable step	▼ 4%
Balance sheet total	€ 661,541 Balance sheet total 2022: € 661,541 First fiscal year in the series	€ 720,981 Balance sheet total 2023: € 720,981 ▲ 9% vs 2022 (€ 661,541) Unchanged	€ 713,909 Balance sheet total 2024: € 713,909 ▼ 1% vs 2023 (€ 720,981) Unchanged	€ 655,182 Balance sheet total 2025: € 655,182 ▼ 8% vs 2024 (€ 713,909) Unchanged	▼ 8%
Employees (FTE)	1.9 Employees (FTE) 2022: 1.9 First fiscal year in the series	2 Employees (FTE) 2023: 2 ▲ 0.1 vs 2022 (1.9) Unchanged	1.8 Employees (FTE) 2024: 1.8 ▼ 0.2 vs 2023 (2) Unchanged	1.8 Employees (FTE) 2025: 1.8 Unchanged (1.8) Unchanged

Key figures of GEVA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to GEVA PHARMA?

What happened at GEVA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 28, 2026 New annual accounts for financial year 2025: profit of € 81,596 (▼ 6% vs 2024). filed late Source: NBB ↗
Sep 1, 1985 New establishment in Oudenaarde. KBO
Aug 9, 1985 Start of the company according to the CBE. KBO

In short

From € 93,505 profit in 2022 to € 81,596 profit in 2025.

Paid € 96,171 in corporate taxes since 2022.

Best year ever: 2023, with € 129,688 profit.

On average € 127,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Conrad Pharma 100%

The stake of Conrad Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

GEVA PHARMA

Behind GEVA PHARMA are Philippe Verzele and Conrad Pharma BV. The shares are held by Conrad Pharma (100%).

Directors

According to the 2025 annual accounts

Philippe Verzele

Director

Also active at: VERZELE PHARMA ZWALM, Conrad Pharma, DECAPHAR, VERZELE PHARMA

Conrad Pharma BV

Director · represented by Vanessa Pluym

Also active at: VERZELE PHARMA ZWALM, DECAPHAR, VERZELE PHARMA

Shareholders

Conrad Pharma

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Diependale 8

9700 Oudenaarde

2.027.566.155

Markt 3

9700 Oudenaarde

Active since 1 September 1985

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

VERZELE PHARMA ZWALM same network

€ 76,445 gross margin · 2025

Conrad Pharma same network

€ 504,793 gross margin · 2025

DECAPHAR same network

€ 300,895 gross margin · 2025

VERZELE PHARMA same network

€ 186,426 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0427.597.576

VAT number

BE 0427.597.576

Registered office

Diependale 8, 9700 Oudenaarde

Names & denominations

GEVA PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 August 1985

Peppol

Active · Active since 19 Nov 2025

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

GEVA PHARMA

Financials

What happened to GEVA PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions